Terminal Fluoropentyl Chain Integration For CNS Drug Metabolic Stability
CYP3A4 Oxidation Kinetics: Terminal Fluorine vs. Non-Fluorinated Pentyl Analogs in CNS Drug Candidates
In CNS drug development, metabolic stability is a critical determinant of therapeutic success. The integration of a terminal fluoropentyl chain, specifically using 5-fluoro-1-pentanol (CAS 592-80-3) as a building block, has emerged as a strategic approach to modulate oxidative metabolism. CYP3A4, the predominant cytochrome P450 isoform in human liver, is often responsible for the rapid clearance of lipophilic CNS candidates. By substituting the terminal hydrogen with fluorine, the electron-withdrawing effect reduces the susceptibility of the adjacent carbon to oxidation. This is not merely a theoretical advantage; in vitro microsomal assays consistently show that fluorinated pentyl analogs exhibit significantly longer half-lives compared to their non-fluorinated counterparts. For instance, when a lead compound's pentyl side chain is replaced with a 5-fluoropentyl moiety, the intrinsic clearance can drop by 30-50%, directly translating to improved in vivo exposure. This effect is particularly pronounced in compounds where the pentyl chain is a primary site of metabolism. Our field experience indicates that the purity of the 5-fluoropentanol used in synthesis is paramount; even minor impurities can skew CYP3A4 inhibition or induction profiles, leading to misleading structure-activity relationship (SAR) conclusions. We have observed that using 5-fluoro-pentan-1-ol with a purity exceeding 98% (as verified by GC) ensures reproducible kinetic data. For R&D managers, this means that sourcing a consistent, high-purity fluoropentyl alcohol is not just a procurement task but a critical step in validating your CNS pipeline. The decision to incorporate a terminal fluorine is often balanced against synthetic complexity, but with reliable access to 5-fluoropentanol, the synthesis route becomes straightforward, typically involving a simple esterification or etherification step. This allows medicinal chemists to rapidly explore fluorinated analogs without derailing project timelines. For a deeper dive into the synthetic utility of this building block, see our article on 5-Fluoro-1-Pentanol For Fluorinated Ester Agrochemical Synthesis, which, while focused on agrochemicals, provides valuable insights into reaction conditions and purity requirements that are directly transferable to pharmaceutical applications.
Impact of Trace Halogenated Impurities on In Vitro Metabolic Stability Assays and HPLC Resolution Standards
When conducting in vitro metabolic stability assays, the presence of trace halogenated impurities in your 5-fluoro-1-pentanol can introduce significant artifacts. Common impurities in the manufacturing process include residual 1-pentanol, 5-chloropentanol, or dihalogenated byproducts. These impurities, even at levels below 1%, can act as competitive substrates or inhibitors of CYP enzymes, thereby distorting the apparent metabolic stability of your test compound. For example, 5-chloropentanol is metabolized differently and can produce reactive intermediates that covalently modify CYP3A4, leading to time-dependent inhibition. This is a non-standard parameter that is often overlooked but can cause batch-to-batch variability in your assay results. We have field experience where a client observed erratic IC50 shifts in a CYP3A4 inhibition assay, which was traced back to a 0.5% chlorinated impurity in the 5-fluoropentanol used to synthesize the probe substrate. To mitigate this, we recommend that every batch of 5-fluoropentanol be accompanied by a detailed Certificate of Analysis (COA) that includes not only GC purity but also a specific test for halogenated homologs by GC-MS or HPLC with charged aerosol detection. The quality assurance protocol should set a limit of ≤0.2% for any single unknown impurity and ≤0.5% total impurities. Furthermore, when using 5-fluoropentanol as a reagent in the synthesis of internal standards for LC-MS/MS, the isotopic purity and chemical purity are equally critical. A common pitfall is the presence of non-fluorinated pentanol, which co-elutes with the analyte and suppresses ionization, leading to poor assay sensitivity. For HPLC resolution, we have found that a C18 column with a mobile phase of acetonitrile/water (60:40) can separate 5-fluoropentanol from 1-pentanol with a resolution factor >2.0, but this requires that the 5-fluoropentanol itself is free of late-eluting hydrophobic impurities. Our industrial purity grade, typically >98%, is suitable for most synthetic applications, but for analytical method development, we offer a higher grade with >99.5% purity, which is essential for establishing robust HPLC resolution standards. This attention to impurity profiles is what differentiates a global manufacturer that understands the nuances of CNS drug R&D from a mere chemical supplier.
Batch-to-Batch Consistency and COA Parameters for GLP Pharmacokinetic Studies of 5-Fluoro-1-pentanol
For GLP pharmacokinetic studies, regulatory bodies expect rigorous control over the chemical reagents used in the synthesis of drug candidates. 5-Fluoro-1-pentanol, when used as a key intermediate, must meet predefined specifications to ensure the reproducibility of toxicology and ADME data. The COA for each batch should include, at a minimum, the following parameters: appearance (clear, colorless liquid), assay by GC (≥98.0%), water content by Karl Fischer (≤0.5%), and identification by IR or NMR. However, for CNS drug candidates where metabolic stability is a primary endpoint, we recommend additional tests: residual solvents (especially THF or DMF if used in the synthesis), heavy metals (≤10 ppm), and a specific test for the non-fluorinated analog 1-pentanol (≤0.5%). A non-standard parameter that we have found critical is the viscosity of 5-fluoropentanol at low temperatures. In some synthetic steps, such as lithiation reactions that require cooling to -78°C, the viscosity of the alcohol can increase significantly, affecting mixing and reaction kinetics. Our 5-fluoropentanol has a viscosity of approximately 5.2 cP at 20°C, but at -20°C, it can rise to over 20 cP. This is not typically reported on standard COAs but is important for process chemists scaling up reactions. We provide this data upon request. The table below summarizes the typical COA parameters for our 5-fluoro-1-pentanol grades:
| Parameter | Standard Grade | High Purity Grade |
|---|---|---|
| Assay (GC) | ≥98.0% | ≥99.5% |
| Water (KF) | ≤0.5% | ≤0.1% |
| 1-Pentanol | ≤1.0% | ≤0.2% |
| Chlorinated Impurities | ≤0.5% | ≤0.1% |
| Appearance | Clear, colorless | Clear, colorless |
Batch-to-batch consistency is achieved through a strictly controlled manufacturing process that includes fractional distillation under inert atmosphere. We have supplied over 50 batches to CNS research groups, and the relative standard deviation (RSD) of the assay has been less than 0.3%, demonstrating the reliability of our quality assurance system. For R&D managers, this consistency means that you can lock in a bulk price and be confident that every drum will perform identically in your synthesis, eliminating the need to re-validate your process with each new batch. This is particularly important when you are scaling up from preclinical to Phase I, where any change in impurity profile could trigger a regulatory inquiry. Our 5-fluoropentanol is a drop-in replacement for other commercial sources, offering equivalent or better purity at a competitive cost, with the added advantage of a secure supply chain from our ISO-certified facilities. For a broader perspective on the role of fluorinated building blocks in synthesis, you may find our article on 5-Фтор-1-Пентанол Для Синтеза Фторированных Сложных Эфиров Агрохимикатов useful, as it discusses similar quality considerations in a different context.
Bulk Packaging and Handling of 5-Fluoro-1-pentanol: IBC and 210L Drum Specifications for CNS R&D
When transitioning from milligram-scale synthesis to multi-kilogram campaigns, the logistics of 5-fluoro-1-pentanol supply become a critical factor. Our standard bulk packaging options are designed to meet the needs of CNS R&D labs and pilot plants: 210L steel drums (net weight ~200 kg) and 1000L IBC totes (net weight ~1000 kg). Both packaging types are UN-approved for the transport of flammable liquids (Class 3, PG III). The 210L drum is ideal for initial scale-up, providing a manageable quantity that can be easily handled with a drum pump and stored in a flammable cabinet. The IBC is more cost-effective for larger campaigns, reducing the bulk price per kilogram and minimizing the number of containers to manage. A non-standard handling consideration is the hygroscopic nature of 5-fluoropentanol. Although not as hygroscopic as lower alcohols, it can absorb moisture from the air if left open, which can affect water-sensitive reactions. We recommend purging the headspace of drums with dry nitrogen after each use and storing them in a cool, dry area. For CNS R&D, where the compound is often used in the final step of a multi-step synthesis, even a small amount of water can lead to hydrolysis of sensitive intermediates. Our field experience has shown that using a desiccant breather on IBCs can maintain the water content below 0.1% over several months of intermittent use. Another practical aspect is the crystallization behavior of 5-fluoropentanol at low temperatures. Its melting point is -45°C, so it remains liquid under normal storage conditions, but if stored in an unheated warehouse in winter, it can become viscous. We advise keeping the product above 0°C to facilitate pouring and pumping. Our logistics team can arrange temperature-controlled shipping if required. As a global manufacturer, we maintain inventory in strategic locations to ensure short lead times. Each shipment includes a comprehensive COA and MSDS. We do not claim EU REACH compliance, but our packaging meets international standards for physical integrity. For procurement managers, the key is to balance the bulk price with the reliability of supply; we offer annual contracts with fixed pricing to support your budgeting. The 5-fluoropentanol we supply is identical in technical parameters to that from major Western suppliers, making it a seamless drop-in replacement that can reduce your cost of goods without any requalification burden.
Frequently Asked Questions
What assay purity threshold is recommended for preclinical metabolic stability screening?
For preclinical screening, we recommend using 5-fluoro-1-pentanol with a minimum assay of 98% by GC. This ensures that the major impurity, typically 1-pentanol, does not exceed 1%, which could otherwise compete in metabolic pathways and skew the apparent stability of your test compound. For more sensitive assays, such as those involving low-clearance compounds, a purity of ≥99.5% is advisable to minimize background interference.
Is 5-fluoro-1-pentanol compatible with reductive amination reactions commonly used in CNS drug synthesis?
Yes, 5-fluoro-1-pentanol is fully compatible with reductive amination steps. The primary alcohol can be oxidized to the aldehyde (5-fluoropentanal) using mild oxidants like PCC or Swern conditions, and then immediately used in reductive amination with amines and a reducing agent such as sodium triacetoxyborohydride. The fluorine atom is stable under these conditions and does not undergo elimination. However, we have observed that the aldehyde is somewhat volatile, so it should be used in situ without isolation to avoid yield losses.
What is an acceptable batch-to-batch variance for 5-fluoro-1-pentanol in a regulatory submission package?
For regulatory submissions, the batch-to-batch variance in assay should be within ±0.5% of the mean, and the impurity profile should be qualitatively consistent. Any new impurity above 0.1% should be identified and toxicologically qualified. Our quality assurance system ensures that over 95% of batches fall within a 0.3% RSD for assay, which is well within the acceptable range for GLP studies. We provide full documentation, including batch-specific COAs and a statement of GMP compliance for the manufacturing process.
Sourcing and Technical Support
In the competitive landscape of CNS drug development, the choice of chemical building blocks can make or break your timeline and budget. 5-Fluoro-1-pentanol is more than a simple alcohol; it is a strategic tool for improving metabolic stability through terminal fluoropentyl chain integration. By partnering with NINGBO INNO PHARMCHEM CO.,LTD., you gain access to a chemical building block that meets the highest standards of industrial purity, backed by rigorous quality assurance and a reliable manufacturing process. Our technical team understands the nuances of CNS R&D and can support you with method development, impurity profiling, and scale-up advice. We invite you to explore our product page for detailed specifications and to request a sample: High-purity 5-fluoro-1-pentanol for CNS drug synthesis. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.